Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Kora Saúde R$770 million IPO
We advised the joint bookrunners on the IPO and São Paulo Stock Exchange listing
Magnolia Medical Technologies patent litigation against Kurin
We are serving as lead trial counsel for Magnolia Medical in an action against its sole competitor
Signify Health trade-secret case against CareCentrix
We are defending Signify Health against trade-secret-misappropriation and related claims
Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Viveo R$1.9 billion IPO
We advised Viveo and the selling shareholders on its IPO and São Paulo Stock Exchange listing
LivaNova $345 million equity offering
We advised the underwriters on the SEC-registered offering
New Frontier Health going-private transaction
We are advising the special committee of the board of New Frontier Health in connection with its going-private acquisition
Nurix Therapeutics $150 million at-the-market offering
We advised the sales agent on the stock offering
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing